FINWIRES · TerminalLIVE
FINWIRES

HKG:6998

2 stories mentioning HKG:6998Updated 22m ago

Every FINWIRES story that references HKG:6998, newest first.

Asia

Edding Genor Completes First Patient Dosing in Breast Cancer Drug Trial; Shares Climb 4%

Edding Genor Group (HKG:6998) completed the first subject dosing in a phase Ib/II clinical trial of GB268, according to a Thursday Hong Kong bourse said.Shares of the company were up nearly 4% in Friday afternoon trading.The drug is for the treatment of locally advanced unresectable or metastatic breast cancer.

HKG:6998
Asia

Genor Biopharma Receives China Nod for Breast Cancer Drug Trial

Genor Biopharma (HKG:6998) received Chinese regulatory approval to begin human trials of GB268 in breast cancer, according to a Thursday filing with the Hong Kong bourse.The firm plans to conduct a phase 1b/2 clinical trial of the drug in combination based regimens.

HKG:6998

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6998 in your portfolio
WheelAI
WheelAI
Analyze HKG:6998 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6998